Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 8
Submit an article Journal homepage
171
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Titas BanerjeeDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAORCID Iconhttps://orcid.org/0000-0001-8077-7888View further author information
ORCID Icon,
Matthew NewmanDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Andy ChenDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Richard T. MaziarzDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Levanto SchachterDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Stephen E. SpurgeonDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
&
Anusha VallurupalliDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5003-807XView further author information
ORCID Icon show all
Pages 1472-1475 | Received 03 Mar 2023, Accepted 19 Apr 2023, Published online: 07 Jun 2023
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

SES: research funding: Genentech, Janssen, Pharmacyclics, Bristol Meyers/Celgene, Merck, Gilead Sciences, Acerta Pharma, BeiGene, Genmab, Incyte, and Morphosys. Consultancy: Genetech Advisory Board: Astra Zeneca and Janssen. RTM: research funding: BMS, Novartis, and Orca Bio. Consultant services: CRISPR Therapeutics, Incyte, Novartis, Bristol-Myers Squibb/Celgene, Allovir, and Gilead/Kite. Scientific Advisory Board: Artiva Therapeutics. DSMB membership: Novartis, Athersys, Vor Pharma, and Century Therapeutics. AC: clinical trial funding: Novartis, Fate Therapeutics, and AstraZeneca. Consultancy: Kite, Intellia Therapeutics, and Elsevier. AV: clinical trial funding: Genmab, Genentech, and ADC Therapeutics.

Additional information

Funding

This work was funded by the Knight Cancer Institute’s Leukemia and Lymphoma Distinguished Scholar Fund.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.